I think the exasperation with the share price comes partially how fast this dropped from .0034 to .0007 after FDA didn't approve actipatch two years ago. Now with FDA approval ten months ago, and all the great progress the past several months on partnerships and marketing agreements, I think this may be why the pps isn't now past the previous close of .0034. I agree with swordfish that those that got in on the cheap are taking profits, they probably are not longs. I expect after consolidation this will advance more quickly as reports of revenue gains inspire more investors to get in for larger future gains. My humble opinion.
BioElectronics Corporation (BIEL) Stock Research Links